Yes, Proteus, Morganella, and Providencia have inherent reduced susceptibility to imipenem
These organisms demonstrate intrinsic resistance mechanisms to imipenem specifically, while often maintaining susceptibility to other carbapenems like meropenem and ertapenem. This is a critical distinction that directly impacts empiric antibiotic selection and treatment outcomes.
Mechanism of Reduced Susceptibility
The FDA drug label for imipenem explicitly states that imipenem is "a potent inhibitor of beta-lactamases from certain Gram-negative bacteria which are inherently resistant to most beta-lactam antibacterials, e.g., Pseudomonas aeruginosa, Serratia spp., and Enterobacter spp." 1. While this doesn't explicitly list Proteus, Morganella, and Providencia, the clinical and research evidence clearly demonstrates this pattern.
The resistance mechanism involves alterations in penicillin-binding proteins (PBPs), particularly PBP 1A and PBP 2. Research demonstrates that imipenem-resistant Proteus mirabilis strains show decreased PBP 1A expression and reduced PBP 2 affinity for imipenem 2. This is an intrinsic mechanism, not acquired through plasmid-mediated resistance.
Clinical Evidence of Differential Carbapenem Susceptibility
The most compelling evidence comes from comparative susceptibility data:
- In a study of Proteus mirabilis isolates, approximately 90% were susceptible to ertapenem compared with ≤25% susceptible to imipenem 3
- Meropenem demonstrated 8 to 16 times lower MICs than imipenem against Proteus, Morganella, and Providencia species 4
- A clinical study of Morganella morganii bacteremia found 19.4% imipenem-resistant isolates, while 95.8% remained ceftazidime-susceptible 5
This paradoxical pattern—where organisms are resistant to imipenem but susceptible to third-generation cephalosporins and other carbapenems—is pathognomonic for intrinsic resistance rather than acquired carbapenemase production.
Practical Clinical Implications
When treating infections caused by Proteus, Morganella, or Providencia:
Avoid imipenem as first-line therapy for these organisms, even if susceptibility testing is pending
Prefer meropenem or ertapenem if carbapenem therapy is indicated—these maintain significantly better activity 3, 4, 6
Consider alternative agents with excellent activity:
Monitor for treatment failure if imipenem is inadvertently used—bactericidal activity is significantly reduced, with regrowth occurring in 80-90% of cases after 24 hours 4
Important Caveats
The FDA label does list Morganella morganii, Proteus vulgaris, and Providencia rettgeri as organisms for which imipenem has demonstrated activity in clinical infections 1. However, this reflects approved indications based on historical clinical trials, not optimal susceptibility profiles. The more recent surveillance data 3, 5, 9 and mechanistic studies 4, 2 clearly demonstrate reduced susceptibility compared to other treatment options.
The key clinical pitfall: Assuming all carbapenems have equivalent activity against these organisms. The OprD porin alterations that cause imipenem resistance in Pseudomonas 10 operate through a different mechanism than the PBP alterations in Proteeae, but both result in carbapenem-specific resistance patterns that clinicians must recognize.
When susceptibility testing shows imipenem resistance in these organisms, do not assume pan-carbapenem resistance—test meropenem and ertapenem separately, as they frequently remain active 3, 6.